WHO ICTRP trial
A Single Arm, Open, Single Center Phase II Clinical Study of Adebrelimab…
ChiCTR2300075166 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300075166 |
|---|---|
| Public title | A Single Arm, Open, Single Center Phase II Clinical Study of Adebrelimab Combined with Chemotherapy for Sequential Thoracic Radiotherapy and Apatinib in the Treatment of Extensive Small Cell Lung Cancer |
| Scientific title | A Single Arm, Open, Single Center Phase II Clinical Study of Adebrelimab Combined with Chemotherapy for Sequential Thoracic Radiotherapy and Apatinib in the Treatment of Extensive Small Cell Lung Cancer |
| Primary sponsor | Qingdao University Affiliated Qingdao Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | small cell lung cancer |
| Interventions | Adelbilimab combined with chemotherapy, sequential chest radiotherapy, and apatinib treatment group:After 4-6 cycles of adelbilimab+carboplatin+etoposide Adelbilimab+chest radiation therapy (radiation dose of 50Gy ± 10%/25f) Adebelizumab… |
| Registration date | Aug 28, 2023 |
| Target size | Adelbilimab combined with chemotherapy, sequential chest radiotherapy, and… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: